Slit lamp

Hexiris Welcomes Dr. Paul Harasymowycz to Its Scientific Committee

Retrieved on: 
Tuesday, April 2, 2024
McGill University, Glaucoma, Health, Pressure, CUO, Disease, Associate, Risk, Patient, Knowledge, Research, MD, Slit lamp, Ophthalmology, Publication, Medical director, FDA, Glaucoma surgery, Medical device

DIEPPE, New Brunswick, April 02, 2024 (GLOBE NEWSWIRE) -- Hexiris Inc. (“Hexiris” or the “Company”), a medical device firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that Dr. Paul Harasymowycz, renowned ophthalmologist and recognized innovator in MIGS techniques, has joined Hexiris’s Scientific Committee.

Key Points: 
  • DIEPPE, New Brunswick, April 02, 2024 (GLOBE NEWSWIRE) -- Hexiris Inc. (“Hexiris” or the “Company”), a medical device firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that Dr. Paul Harasymowycz, renowned ophthalmologist and recognized innovator in MIGS techniques, has joined Hexiris’s Scientific Committee.
  • “We are proud that Dr. Harasymowycz has agreed to join our scientific committee,” said Dr. Nir Shoham-Hazon, Co-Founder and Co-CEO of Hexiris.
  • Over the past 20 years, Dr. Harasymowycz has distinguished himself through his extensive research and more than 90 publications in national and international scientific journals, and book chapters on glaucoma.
  • As a result, the Hexiris MIGS Solution is expected to generate considerable cost benefits for the health system.

Hexiris Pharma Welcomes World-Renowned Ophthalmologist Dr. Ike Ahmed to its Scientific Committee

Retrieved on: 
Monday, October 30, 2023
Knowledge, American Academy of Ophthalmology, FDA, Research, AGS, American Glaucoma Society, Vision, Slit lamp, ASCRS, Refractive surgery, ISGS, Glaucoma, MIGS, Pressure, MD, University of Utah, AAO, Glaucoma surgery, Alan, University, COS, Cataract, Trillium Health Partners, University of Toronto, Eye, Visual Science, CGS, American Society of Cataract and Refractive Surgery, International Society, ARVO, Scientific Committee on Emerging and Newly Identified Health Risks, Patient, Diagnosis, Medical device, Ophthalmology

DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.

Key Points: 
  • DIEPPE, New Brunswick, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Hexiris Pharma Inc. (“Hexiris Pharma” or the “Company”), a pharmaceutical firm dedicated to advancing and simplifying Minimally Invasive Glaucoma Surgery (MIGS), is pleased to announce that world-renowned ophthalmologist Dr. Ike Ahmed will join Hexiris Pharma’s Scientific Committee.
  • “We are truly honoured that Dr. Ahmed has agreed to join Hexiris Pharma’s Scientific Committee,” said Dr. Nir Shoham-Hazon, Co-Founder and Co-CEO of Hexiris Pharma.
  • I’m pleased to be joining the Scientific Committee at Hexiris Pharma and join in the important work of improving the lives of patients and bringing new solutions and opportunities to ophthalmologists,” said Dr. Ahmed.
  • He has given over 750 scientific presentations thus far in his career, including 31 visiting professor’s lectures around the world.

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Retrieved on: 
Wednesday, October 4, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Contact, Ernest, Cerebral edema, Palace, Employment, Pain, Telecanthus, Incidence, Hilton New Orleans Riverside, Steroid, Viral, Macular edema, Herpes simplex, NYSE, Chickenpox, Magazine Street, Canal Street, Conjunctiva, EYE, Tchoupitoulas Street, Risk, Pigment, Intraocular pressure, SM, Optic nerve, FDA, INA War Museum, Iris, Andhra Pradesh Decentralisation and Inclusive Development of All Regions Act, 2020, Fungal infection, Poydras Street, Sclera, Eye, Bausch, History, Slit lamp, Glaucoma, Ocular hypertension, DED, Cornea, IOP, Contact lens, Infection, American Academy, Inflammation, Johnson & Johnson Vision, Vaccinia, Bausch & Lomb, Lens (vertebrate anatomy), Visual acuity, Pharmaceutical industry, Medical device, Hospital, Telescopic sight, Hotel, Gasoline, Nursing, Dietary supplement, Vaccine, Blinking, O.D, Patient

Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Key Points: 
  • Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
  • Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
  • The Bausch + Lomb schedule at AAOpt:
    “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.
  • “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.

Choice of premium exam chairs enhances Reliance Optometry Workplace exam lane solution

Retrieved on: 
Saturday, June 24, 2023
Reliance, IOP, GAT, Workplace, AOA, Optometry, Slit lamp, Charcoal, Patient, Furniture, Nursing, Health care

MASON, Ohio, June 24, 2023 /PRNewswire-PRWeb/ -- Haag-Streit USA, the leading US distributor of gold-standard ophthalmic diagnostic devices, surgical microscopes, and virtual reality-based medical simulators, is pleased to announce it now offers two exam chair options as part of the Reliance Optometry Workplace.

Key Points: 
  • Haag-Streit USA enhances the Reliance Optometry Workplace with the option of the Reliance 6200 exam chair.
  • Previously, the Reliance Optometry Workplace included the Reliance 520 examination chair as standard.
  • The price for the Reliance Optometry Workplace will remain the same, regardless of the chosen chair option.
  • The Reliance Optometry Workplace optometry exam lane solution is only available in the USA.

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

Retrieved on: 
Monday, May 8, 2023
Human, Arm, Eyelash, Education, OD, Cataract, Attention, TARS, Inflammation, Science, Blepharitis, Slit lamp, Eyelid, MD, Patient, Infestation, Red, Disease, Pharmaceutical industry, Telescopic sight, Nursing, Cosmetics, Demodex

IRVINE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the launch of “Don’t Freak Out. Get Checked Out.”, a disease education campaign designed to encourage patients who may have Demodex blepharitis to visit their eye care provider for an eyelid check. In support of Healthy Vision Month in May, the first of its kind campaign is designed to support patients on their journey to identify the cause of their eyelid discomfort.

Key Points: 
  • Get Checked Out.”, a disease education campaign designed to encourage patients who may have Demodex blepharitis to visit their eye care provider for an eyelid check.
  • In support of Healthy Vision Month in May, the first of its kind campaign is designed to support patients on their journey to identify the cause of their eyelid discomfort.
  • Demodex blepharitis is caused by an overpopulation of Demodex mites, the most common ectoparasites found in humans.
  • “Demodex blepharitis patients often complain of severe discomfort and can be extremely conscious of how their eyes feel all day.

Norlase Receives FDA 510(k) Clearance and CE Mark Approval For ECHO™ Green Pattern Laser

Retrieved on: 
Friday, May 5, 2023
Retina, CE marking, MEMS, Slit lamp, CE, ECHO, Ophthalmology, Surgeon, FDA, Patient, Medical imaging, 3D printing

BALLERUP, Denmark and REDWOOD CITY, Calif., May 5, 2023 /PRNewswire/ -- Norlase, a leading global ophthalmic laser manufacturer developing next-generation laser solutions, today announced it has received both FDA 510(k) clearance and CE Mark approval for the ECHO Green Pattern Laser photocoagulator. ECHO is an industry-first, portable scanning laser photocoagulator utilizing MEMS technology. The laser and scanner are completely integrated into a single delivery device that attaches to compatible slit lamps. Other exclusive features include no external fiber, a wireless user interface, µSec Mode for tissue-sparing treatment, and voice control of patterns and parameters. With an affordable price point, ECHO will make pattern scanning technology accessible to more doctors worldwide, equipping them with the tools to treat efficiently and increase patient throughput.

Key Points: 
  • BALLERUP, Denmark and REDWOOD CITY, Calif., May 5, 2023 /PRNewswire/ -- Norlase, a leading global ophthalmic laser manufacturer developing next-generation laser solutions, today announced it has received both FDA 510(k) clearance and CE Mark approval for the ECHO Green Pattern Laser photocoagulator.
  • The laser and scanner are completely integrated into a single delivery device that attaches to compatible slit lamps.
  • "The FDA clearance and CE mark approval of ECHO is our most significant milestone to date," said Oliver Hvidt, CEO and Co-Founder of Norlase.
  • Early adopters of the ECHO pattern laser have shared positive experiences about the laser's functionality and treatment results.

Norlase Receives FDA 510(k) Clearance and CE Mark Approval For ECHO™ Green Pattern Laser

Retrieved on: 
Friday, May 5, 2023
Retina, CE marking, MEMS, Slit lamp, CE, ECHO, Ophthalmology, Surgeon, FDA, Patient, Medical imaging, 3D printing

BALLERUP, Denmark and REDWOOD CITY, Calif., May 5, 2023 /PRNewswire/ -- Norlase, a leading global ophthalmic laser manufacturer developing next-generation laser solutions, today announced it has received both FDA 510(k) clearance and CE Mark approval for the ECHO Green Pattern Laser photocoagulator. ECHO is an industry-first, portable scanning laser photocoagulator utilizing MEMS technology. The laser and scanner are completely integrated into a single delivery device that attaches to compatible slit lamps. Other exclusive features include no external fiber, a wireless user interface, µSec Mode for tissue-sparing treatment, and voice control of patterns and parameters. With an affordable price point, ECHO will make pattern scanning technology accessible to more doctors worldwide, equipping them with the tools to treat efficiently and increase patient throughput.

Key Points: 
  • BALLERUP, Denmark and REDWOOD CITY, Calif., May 5, 2023 /PRNewswire/ -- Norlase, a leading global ophthalmic laser manufacturer developing next-generation laser solutions, today announced it has received both FDA 510(k) clearance and CE Mark approval for the ECHO Green Pattern Laser photocoagulator.
  • The laser and scanner are completely integrated into a single delivery device that attaches to compatible slit lamps.
  • "The FDA clearance and CE mark approval of ECHO is our most significant milestone to date," said Oliver Hvidt, CEO and Co-Founder of Norlase.
  • Early adopters of the ECHO pattern laser have shared positive experiences about the laser's functionality and treatment results.

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Tradition, Intraocular lens, Aperture, ASCRS, Astigmatism, Pain, Employment, Telecanthus, Incidence, Patient, Outcome, Viral, Steroid, Herpes simplex, NYSE, Chickenpox, Very-small-aperture terminal, Conjunctiva, Cornea, Comparative Effectiveness Research Translation Network, SM, Optic nerve, Cataract, FDA, Emerging technologies, Fungal infection, Refractive surgery, Use, Sclera, Eye, Bausch, History, Thought, American Society of Cataract and Refractive Surgery, Slit lamp, ARMOR, Glaucoma, DED, IOP, Contact lens, Infection, OVD, Inflammation, Vaccinia, Bausch & Lomb, Range, Convention (norm), Visual acuity, Society, Pharmaceutical industry, Telescopic sight, Telescope, Wood drying, Dentistry, Hospital, Retail, Veterinary medicine, Fused quartz, Vaccine, Dietary supplement, Emmetropia, Refraction, IOL

The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.

Key Points: 
  • The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.
  • Others include a retrospective chart review on the use of LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% in refractive surgery and numerous presentations focused on Bausch + Lomb surgical IOL pipeline programs.
  • New data from the Bausch + Lomb Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study will also be presented.
  • “Clinical Evaluation of the Outcomes of Two Preloaded Monofocal IOLs Implanted Bilaterally in Cataract Patients.” Shultz et al.

Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program

Retrieved on: 
Monday, April 24, 2023
Slit lamp, KRYS, Corneal abrasion, ARVO, DEB, Research and development, University, AE, Hospital, Eye, Suma, Doctor of Philosophy, Assistant, Concha bullosa, Bascom Palmer Eye Institute, Pannus, Ophthalmology, HM, Patient, Association for Research in Vision and Ophthalmology, Rare, Research, FDA, Visual acuity, Pharmaceutical industry, Telescopic sight

“It is exciting to potentially advance a topical treatment for patients with ocular complications associated with DEB.”

Key Points: 
  • “It is exciting to potentially advance a topical treatment for patients with ocular complications associated with DEB.”
    The data presented describes the first application of B-VEC to treat ocular complications in a patient with DEB under a compassionate use program.
  • The patient presented with cicatrizing conjunctivitis and underwent surgical symblepharon lysis with pannus removal in the right eye.
  • B-VEC was administered to the patient’s right eye at regular intervals following surgery in addition to routine post-surgical management.
  • Ocular complications are common in patients with DEB, with over half of the patients diagnosed with recessive DEB potentially affected.

Phoenix-Micron, Inc. Announces New, Comprehensive Imaging Software and Redesigned Lens Technology for the Phoenix MICRON® Imaging Platform

Retrieved on: 
Friday, April 21, 2023
Data management, Calibration, ERG, Workflow, Eye, Research, Software suite, Slit lamp, Animal, Application, OCT, Annotation, Create, Software, Wool, Medical imaging, Telescopic sight, Phoenix

BEND, Ore., April 21, 2023 /PRNewswire-PRWeb/ -- Phoenix-Micron, Inc., a leader in ophthalmic imaging technology, today announced the release of the new MICRON® Software Suite and the MICRON LT2 lens technology. The new MICRON Software Suite streamlines the ophthalmic imaging workflow and captures and manages even more valuable research data about small subject animals. Also announced today, the patent-pending, MICRON LT2 lens technology represents a complete redesign of MICRON objective lenses that makes precision optical alignment easier and more repeatable. Both innovations are compatible with the MICRON IV and all-new MICRON 5 imaging platforms.

Key Points: 
  • Two new innovations, MICRON Software Suite and MICRON LT2 lens technology, streamline the ophthalmic imaging workflow and deliver new data management capabilities.
  • BEND, Ore., April 21, 2023 /PRNewswire-PRWeb/ -- Phoenix-Micron, Inc., a leader in ophthalmic imaging technology, today announced the release of the new MICRON® Software Suite and the MICRON LT2 lens technology.
  • MICRON Software Suite delivers a user experience designed for researchers imaging the eyes of small animals.
  • MICRON Software Suite offers multiple features that simplify the imaging process and integrate their Phoenix MICRON imaging data all in one place and with an intuitive user experience:
    1.